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Facilitating kidney transplant 
tolerance
Leventhal et al., Sci Transl Med 2012; 4: 124ra28; doi:10.1126/
scitranslmed.3003509
Currently, the most promising approach for human kidney 
transplant tolerance is the development of mixed chimerism 
within the kidney allograft recipient. Leventhal et al. used a 
nonmyeloablative conditioning approach, incorporating three 
pre-transplantation doses of fludarabine (30 mg/kg), two doses 
of cyclophosphamide (50 mg/kg) at day –3 and day +3, and low-
dose total-body irradiation (200 Gy) in combination with an 
infusion of facilitating cells (FCs) to enhance the development 
of donor chimerism before weaning from immuno suppression. 
FCs were enriched from peripheral blood of granulocyte col-
ony-stimulating factor-mobilized living kidney donors at least 2 
weeks before transplantation, by a proprietary approach involv-
ing depletion of graft-versus-host disease (GVHD)-causing anti-
gen-presenting cells. The FC fraction was given on day 1 after 
transplantation and comprised enriched hematopoietic stem cells 
and plasmacytoid precursor dendritic cells. Post-transplantation 
immunosuppression included tacrolimus and mycophenolate 
therapy. Of the eight patients treated, five developed 100% mul-
tilineage chimerism at 1 month and were successfully weaned 
from immunosuppressive therapy, with follow-up ranging from 
6 to 20 months off. The conditioning regimen was well toler-
ated. In the weaned patient group, none developed engraftment 
syndrome secondary to the infusion, donor-specific alloantibody 
sensitization, or GVHD.
The authors performed extensive immunological monitoring 
of their transplant cohort, including identification of the presence 
of a significant number of CD19+ B cells during the first year 
after transplantation. The precise mechanism whereby the FC 
fraction enhances chimerism development and allows donor-
specific tolerance to develop is unclear, but preclinical studies in 
murine models suggest that they may induce antigen-specific T 
regulatory cells. Overall, this work marks another significant step 
toward the realization of kidney transplant tolerance in the clinic.
P. Toby Coates
Bicarbonate-containing  
peritoneal dialysates do not 
preferentially prevent reduction  
in residual renal function
Johnson et al., J Am Soc Nephrol 2012; 23: 1097–1107; doi:10.1681/
ASN.2011121201
Bicarbonate-based dialysate is now the standard for hemodialy-
sis, yet most peritoneal dialysis patients use lactate-containing 
fluids rather than bicarbonate. Several small prospective studies 
with limited follow-up have reported that neutral-pH bicarbo-
nate-containing peritoneal dialysis fluids have had either a ben-
eficial or a neutral effect on the preservation of residual renal 
function. Bicarbonate fluids are typically prepared in dual-cham-
ber bags and, as such, contain less potentially nephrotoxic glu-
cose degradation products following heat sterilization. However, 
these fluids are more expensive to produce and cost substantially 
more than standard lactate-containing peritoneal dialysis fluids. 
Johnson and colleagues conducted a randomized prospective 
trial of bicarbonate-containing compared with standard lactate-
containing dialysates in incident patients starting peritoneal 
dialysis. Patient groups were well matched and had equal train-
ing and were followed for 24 months. There was no difference in 
the rate of loss of residual renal function, the primary outcome 
measure. However, on secondary analysis, the time to anuria 
was greater with bicarbonate-containing dialysates. Although 
the number of patients transferring to hemodialysis was similar 
in both groups, the time to the first episode of peritonitis was 
longer and the peritonitis rate lower with bicarbonate-contain-
ing dialysates. As daily ultrafiltration volumes were greater with 
standard peritoneal dialysates, the increased number of perito-
nitis episodes could have potentially led to episodes of relative 
hypovolemia with acute kidney injury, thus shortening the time 
to anuria. Alternatively, episodes of peritonitis may have been 
treated with nephrotoxic antibiotics, again risking acute kidney 
injury. The reported reduction in episodes of peritonitis remains 
to be explained.
This prospective multicenter trial does not support the use of 
more expensive neutral-pH bicarbonate-containing peritoneal 
dialysates to reduce the rate of loss of residual renal function. 
However, the reduction in the incidence of peritonitis episodes 
warrants further investigation, with further prospective trials spe-
cifically designed to examine peritonitis as a primary end point.
Andrew Davenport
Klotho deficiency and vascular 
disease in chronic kidney disease
Lim et al., Circulation 2012; 125: 2243–2255; doi:10.1161/
CIRCULATIONAHA.111.053405
The role of Klotho (more precisely, a-Klotho) as an obligatory 
co-receptor for the activation of the fibroblast growth factor 
(FGF) receptors FGFR-1 and FGFR-3 by FGF-23 seemed firmly 
established, in line with the observation that the experimental 
deletion of either FGF-23 or Klotho leads to nearly identical 
phenotypes. However, recent doubt has arisen about the con-
cept that Klotho and FGF-23 always have to work together. 
On the one hand, Klotho was shown to exert direct actions 
on the vessel wall in the absence of FGF-23. On the other, 
FGF-23 was found to have Klotho-independent actions on 
the myocardium, at least at high concentrations, such as those 
observed in the uremic state. Lim et al. examine the vascular 
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role of Klotho in more detail. First, they confirm the recent 
observation by Hu et al. that Klotho deficiency potentiates the 
development of human artery calcification. They further dem-
onstrate expression of Klotho, FGFR-1, and FGFR-3 in human 
aortic smooth muscle cells (haSMCs), with downregulation 
in response to high concentrations of calcium and phosphate, 
tumor necrosis factor-a, and uremic serum in the incubation 
milieu, respectively. Klotho downregulation by these factors or 
inhibition of Klotho action by small interfering RNA (siRNA) 
enhances haSMC calcification. Notably, treatment with active 
vitamin D sterols of haSMCs maintained in a procalcific envi-
ronment restores Klotho and FGFR expression and inhibits 
calcification. Finally, the physiological stimulation of haSMC 
survival and proliferation by FGF-23 is shown to be mitigated 
by Klotho siRNA, favoring haSMC transformation into osteo-
blast-like cells. Restoration of FGF-23 responsiveness and pro-
tection against haSMC phenotype change are achieved by full 
Klotho expression. In chronic kidney disease (CKD), kidney 
and parathyroid tissue Klotho content as well as circulating 
Klotho levels decrease progressively. Lim et al. now show that 
vessel wall Klotho and FGFRs also are decreased in CKD. Thus, 
Klotho appears to remain a major player in the CKD-associated 
mineral and bone disorder and cardiovascular disease (Figure).
Tilman B. Drüeke
Inducible podocyte injury and 
proteinuria in transgenic zebrafish
Zhou and Hildebrandt, J Am Soc Nephrol 2012; 23: 1039–1047; 
doi:10.1681/ASN.2011080776
At present, the precise etiology of nephrotic syndrome remains 
unknown in a majority of cases. Podocytes are considered to play 
a major role in glomerular permselectivity, and their damage 
contributes to proteinuria. Mutations in podocyte-specific genes 
and soluble factors contributing to nephrotic syndrome have 
been identified in humans, but research is complicated by the lack 
of a simple, high-throughput test system. Zebrafish are useful for 
testing disease models, including for the kidney. Recently, Zhou 
and Hildebrandt have generated an inducible model of podocyte 
injury in zebrafish. Application of the prodrug metronidazole to 
the transgenic fish induces acute damage specifically to the podo-
cytes, resulting in foot process effacement and podocyte loss. A 
functional assay for proteinuria was included by coexpression of 
green fluorescent protein (GFP)-tagged vitamin D-binding pro-
tein in the transgenic zebrafish. In the transgenic fish, induction 
of podocyte damage led to whole-body edema, and the proximal 
tubules reabsorbed and accumulated the GFP-tagged protein, 
mimicking the phenotype of human nephrotic syndrome.
Thus, this transgenic zebrafish model can be used as a simple 
high-throughput tool for studies of glomerular pathogenesis and 
podocyte regeneration.
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Klotho deficiency in CKD plays a major role in vascular calcification, 
partially via resistance to the action of fibroblast growth factor-23. 
Ca, calcium; Cbfa1, core-binding factor subunit a-1; CKD, chronic 
kidney disease; FGF-23, fibroblast growth factor-23; FGFR-1 and FGFR-3, 
fibroblast growth factor receptors 1 and 3; Pi, phosphate; Runx2, Runt-
related transcription factor 2; TNF-a, tumor necrosis factor-a.
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